Partnership for Health Analytic Research, Beverly Hills, CA, USA.
Am J Manag Care. 2010 Mar;16(3):170-8.
To investigate differences in demographics, physician specialty, and medication use between patients who achieve high versus low ratios of controller to total asthma medications.
Cohort analysis.
We used a Health Insurance Portability and Accountability Act-compliant claims database to identify patients aged 5 to 56 years with persistent asthma during a premeasurement year and a measurement year. Based on values in the measurement year, the ratio of controller to total asthma medications ratio was defined using the following formula: (Units of Controllers) / (Units of Controllers + Relievers). Descriptive analysis and multivariate logistic regression models were used to examine patients with high and low ratios.
The final study group comprised 38,538 patients with persistent asthma; 28,496 (73.9%) had high ratios. Specialty of usual-care physician differed (P <.001), with more high-ratio patients than low-ratio patients having an allergist or pulmonologist. Patients who received combination inhaled corticosteroid-long-acting beta-agonist therapy (odds ratio [OR], 2.4) or leukotriene receptor antagonist therapy (OR, 3.5) were more likely to be in the high-ratio group compared with those dispensed a single inhaled corticosteroid. High-group and low-group assignment could be calculated by partial-year data: assignment based on 1 quarter of data was concordant with assignment based on full-year ratio in 91% of cases (Pearson product moment correlation coefficient, 0.864; kappa statistic, 0.761), and assignment based on 2 quarters of data was concordant with full-year results in 94% of cases (Pearson product moment correlation coefficient, 0.928; kappa statistic, 0.843).
A high ratio of controller to total asthma medications is associated with greater controller adherence and with more controller fills. The ratio can be calculated using 1 or 2 quarters of pharmacy claims data, at a time when intervention may reduce asthma-related exacerbations. Interventions that may improve the ratio include changing from single inhaled corticosteroid therapy and from asthma specialist care.
研究达到高控制药物与总哮喘药物比例和低控制药物与总哮喘药物比例的患者在人口统计学、医生专业和用药方面的差异。
队列分析。
我们使用符合《健康保险流通与责任法案》的索赔数据库,确定了在预测量年度和测量年度期间,年龄在 5 至 56 岁之间的持续性哮喘患者。根据测量年度的值,使用以下公式定义控制药物与总哮喘药物的比例:(控制器单位)/(控制器单位+缓解器单位)。我们使用描述性分析和多变量逻辑回归模型来检查高比值和低比值患者。
最终研究组包括 38538 名患有持续性哮喘的患者;28496 名(73.9%)患者的比值较高。通常情况下,医生的专业也有所不同(P<.001),与低比值患者相比,高比值患者更多地接受过敏症专家或肺病专家的治疗。与接受单一吸入皮质激素治疗的患者相比,接受联合吸入皮质激素长效β激动剂治疗(比值比[OR],2.4)或白三烯受体拮抗剂治疗(OR,3.5)的患者更有可能处于高比值组。高比值组和低比值组的分配可以通过部分年度数据计算得出:基于 1 个季度的数据进行分配,与基于全年比值的分配在 91%的情况下是一致的(皮尔逊积矩相关系数,0.864;kappa 统计量,0.761),基于 2 个季度的数据进行分配,与全年结果在 94%的情况下是一致的(皮尔逊积矩相关系数,0.928;kappa 统计量,0.843)。
高控制药物与总哮喘药物的比值与更高的控制药物依从性和更多的控制药物填充相关。该比值可以使用 1 或 2 个季度的药房索赔数据进行计算,此时干预可能会减少与哮喘相关的恶化。可能改善比值的干预措施包括从单一吸入皮质激素治疗和从哮喘专科治疗转变。